TipRanks
Go Ultimate55% OFF

Stoke Therapeutics (STOK) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Sham Comparator, ZorevunersenDravet SyndromePhase IIIRecruitingA Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeMar 06, 2025―
Stk-001Dravet SyndromePhase IIActive Not RecruitingAn Open-Label Extension Study of STK-001 for Patients With Dravet SyndromeFeb 02, 2021―
Stk-001 - Single Ascending Doses, Stk-001 - Multiple Ascending DosesDravet Syndromephase1AndPhase2CompletedAn Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet SyndromeJun 08, 2020―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Stoke Therapeutics (STOK) have in its pipeline
Stoke Therapeutics STOK is currently developing the following drugs: Sham Comparator, Zorevunersen, Stk-001, Stk-001 - Single Ascending Doses, Stk-001 - Multiple Ascending Doses. These drug candidates are in various stages of clinical development as the company works toward FDA approval.